Understand Mechanism of Action, Maximize Efficacy and Therapeutic Window, and Evaluate Long-Term Clinical Outcomes of Fc Receptor Pathway Targeting Biologics in Autoantibody Mediated Disease.
The field of FcRn receptor targeting is gaining ground-breaking speed as Argenx, Janssen, UCB and Immunovant compete to tackle myasthenia gravis and biopharma invest in transformative immunological therapy for autoimmune diseases as the next big drug opportunity.
Continue reading at fcr-targeted-therapies.com
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2023 Netspective Media LLC. All Rights Reserved.
Built on Mar 24, 2023 at 1:25pm